Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

This study has been terminated.
(Slow accrual)
Information provided by (Responsible Party):
Seppo W. Langer, Danish Oncological Lung Cancer Group Identifier:
First received: December 19, 2008
Last updated: January 23, 2016
Last verified: January 2016
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.

Condition Intervention Phase
Extensive Disease
Small Cell Lung Cancer
Drug: topotecan + cisplatin
Drug: Etoposide + carboplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase III Trial of Topotecan and Cisplatin Versus Etoposide and Carboplatin in the Treatment of Patients With Previously Untreated Small Cell Lung Cancer and Extensive Disease

Resource links provided by NLM:

Further study details as provided by Danish Oncological Lung Cancer Group:

Primary Outcome Measures:
  • 2 years survival [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Response rates [ Time Frame: 2 years ]

Enrollment: 281
Study Start Date: January 2006
Study Completion Date: January 2015
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Topotecan + cisplatin
Drug: topotecan + cisplatin
topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
Active Comparator: B
Etoposide + carboplatin
Drug: Etoposide + carboplatin
Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W

Detailed Description:
Fase III, multicenter randomised trial comparing up to six cycles of carboplatin and etoposide with up to six cycles of topotecan and cisplatin in patients with extensive stage small cell lung cancer and PS 0-3

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed SCLC
  • Extensive stage
  • No prior chemotherapy
  • WHO PS 0-3
  • Adequate organ function (liver, kidney)
  • Adequate hematology (bone marrow)
  • Informed consent

Exclusion Criteria:

  • PS 4
  • Inadequate organ function
  • Uncontrolled infection
  • Concomitant major medical contraindications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00812266

Dept. Oncology, Rigshospitalet
Copenhagen, Denmark
Sponsors and Collaborators
Danish Oncological Lung Cancer Group
Principal Investigator: Seppo W Langer, MD PhD Dept. of Oncology, Rigshospitalet, Copenhagen
  More Information

Responsible Party: Seppo W. Langer, MD pHD, Danish Oncological Lung Cancer Group Identifier: NCT00812266     History of Changes
Other Study ID Numbers: DOLG7
DOLG7 ( Other Identifier: Danish Oncological Lung Cancer Group Number )
Study First Received: December 19, 2008
Last Updated: January 23, 2016

Keywords provided by Danish Oncological Lung Cancer Group:
Extensive disease

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Etoposide phosphate
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors processed this record on May 25, 2017